Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis
Inflammatory Intestinal Diseases · 09.12.2025 · 11 (1) · 29-42
DOI: 10.1159/000549088 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammatory Intestinal Diseases, online erschienen am 09.12.2025. Verfasst von Tareq Alsaleh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, AdventHealth Orlando, Orlando, FL, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Upadacitinib and tofacitinib, oral Janus kinase inhibitors, have demonstrated efficacy and safety in ulcerative colitis (UC) in clinical trials. However, real-world comparative data are limited. We conducted a systematic review and meta-analysis of studies directly comparing upadacitinib to tofacitinib in UC management.
Methods
We conducted a systematic search of multiple databases through August 2025 for studies comparing upadacitinib and tofacitinib for UC management. The primary outcome was steroid-free clinical remission (SFCR) at weeks 8–14. Secondary outcomes included SFCR at later timepoints, clinical and endoscopic remission, biochemical remission, treatment discontinuation, colectomy, and safety. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random effects model. Heterogeneity was assessed using the I2% statistic.
Results
Ten retrospective studies with 2,021 patients (879 upadacitinib and 1,142 tofacitinib) were analyzed. Upadacitinib was associated with significantly higher SFCR at weeks 8–14 (OR 1.98; 95% CI: 1.32–3.97; I2 = 30%), 48–60 weeks (OR 2.32; 95% CI: 1.50–3.58; I2 = 0%), and at the end of study follow-up (OR 3.60; 95% CI: 1.73–3.92; I2 = 0%). Rates of endoscopic and biochemical remission did not differ significantly. Treatment discontinuation was less frequent with upadacitinib (OR 0.51; 95% CI: 0.34–0.77; I2 = 22%). Overall safety was comparable, except for higher odds of acne with upadacitinib (OR 4.30; 95% CI: 1.86–9.95; I2 = 0%).
Conclusion
Upadacitinib may be more effective than tofacitinib in achieving and sustaining SFCR, with better treatment persistence and similar overall safety. Larger, prospective head-to-head trials are needed to validate these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine, AdventHealth Orlando, Orlando, FL, USA.
- Center for Interventional Endoscopy, AdventHealth Orlando, Orlando, FL, USA.
- Gastroenterology and Hepatology, AdventHealth Orlando, Orlando, FL, USA.
- Internal Medicine, Jaber Hospital, Ministry of Health, Kuwait City, Kuwait.
- Internal Medicine, Al-Sabah Hospital, Ministry of Health, Kuwait City, Kuwait.
- Inflammatory Bowel Disease Center, AdventHealth Orlando, Orlando, FL, USA.
Zitieren
APA
Alsaleh, T., Mohammed, A., Farooq, A., Elamin, M., Akl, A., Yassin, K. M., Elnaggar, A., & Seminerio, J. (2025). Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis. Inflammatory Intestinal Diseases, 11(1), 29-42. https://doi.org/10.1159/000549088
Vancouver
Alsaleh T, Mohammed A, Farooq A, Elamin M, Akl A, Yassin KM, et al. Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis. Inflammatory Intestinal Diseases. 2025;11(1):29-42. doi:10.1159/000549088
BibTeX
@article{Alsaleh2025,
author = {Alsaleh, Tareq and Mohammed, Abdul and Farooq, Aimen and Elamin, Magda and Akl, Amr and Yassin, Karim Mohamed and Elnaggar, Ahmed and Seminerio, Jennifer},
title = {Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis},
journal = {Inflammatory Intestinal Diseases},
year = {2025},
volume = {11},
number = {1},
pages = {29--42},
doi = {10.1159/000549088}
}
EUVIMED